Saba Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-295,913
| Closed | -$4.26K | – | 404 |
|
|
2025
Q3 | $4.26K | Hold |
295,913
| – | – | ﹤0.01% | 305 |
|
|
2025
Q2 | $7.04K | Hold |
295,913
| – | – | ﹤0.01% | 290 |
|
|
2025
Q1 | $3.77K | Hold |
295,913
| – | – | ﹤0.01% | 246 |
|
|
2024
Q4 | $2.71K | Hold |
295,913
| – | – | ﹤0.01% | 270 |
|
|
2024
Q3 | $1.75K | Hold |
295,913
| – | – | ﹤0.01% | 342 |
|
|
2024
Q2 | $5.95K | Hold |
295,913
| – | – | ﹤0.01% | 340 |
|
|
2024
Q1 | $26.3K | Hold |
295,913
| – | – | ﹤0.01% | 287 |
|
|
2023
Q4 | $8.14K | Hold |
295,913
| – | – | ﹤0.01% | 421 |
|
|
2023
Q3 | $22.7K | Hold |
295,913
| – | – | ﹤0.01% | 444 |
|
|
2023
Q2 | $19.4K | Hold |
295,913
| – | – | ﹤0.01% | 497 |
|
|
2023
Q1 | $11.9K | Hold |
295,913
| – | – | ﹤0.01% | 683 |
|
|
2022
Q4 | $12.8K | Hold |
295,913
| – | – | ﹤0.01% | 783 |
|
|
2022
Q3 | $24K | Hold |
295,913
| – | – | ﹤0.01% | 926 |
|
|
2022
Q2 | $31K | Hold |
295,913
| – | – | ﹤0.01% | 956 |
|
|
2022
Q1 | $64K | Hold |
295,913
| – | – | ﹤0.01% | 850 |
|
|
2021
Q4 | $124K | Buy |
+295,913
| New | +$136K | ﹤0.01% | 692 |
|
Other funds holding CEROW
Saba Capital Management's CEROW Position: Q4 2025 in Review
Saba Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q4 2025, closing a stake of 295,913 shares — an estimated $4.26K sold.
Saba Capital Management first reported a position in CEROW in Q4 2021 and held it in 16 quarters. The position peaked at $124K in Q4 2021. 1 fund tracked by Wall St. Rank holds CEROW as of Q4 2025.
- Saba Capital Management reported no remaining CERo Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
- Saba Capital Management sold 295,913 CERo Therapeutics Warrants shares in Q4 2025, an estimated $4.26K.
- Saba Capital Management first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 16 quarters.
- Saba Capital Management's CERo Therapeutics Warrants position peaked at $124K in Q4 2021.
- 1 fund tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2025.
Based on Saba Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.